FDG-PET to monitor early response to infliximab in refractory systemic sarcoidosis
| Autor: | Hélène Schuhmacher, Stéphane Zuily, Denis Wahl, Pierre Olivier, Alexandra Desvignes, Denis Régent, Leilah Saadi |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Pathology medicine.diagnostic_test Systemic sarcoidosis business.industry Disease medicine.disease Infliximab medicine.anatomical_structure Refractory Positron emission tomography medicine Tumor necrosis factor alpha Sarcoidosis Radiology business Nose medicine.drug |
| Zdroj: | Respiratory Medicine Extra. 3:178-180 |
| ISSN: | 1744-9049 |
| DOI: | 10.1016/j.rmedx.2007.09.004 |
| Popis: | Summary Background Systemic sarcoidosis can result in dramatic manifestations despite therapeutic escalation. Tumor necrosis factor (TNFα) has a key role in this disease and antagonists of TNFα have been successfully used as an alternative to conventional therapy. We report a case of refractory sarcoidosis with mediastinal, bone and ear, nose, throat (ENT) lesions. Methods In this patient we monitored response to treatment by infusions of the anti-TNFα antibody, infliximab, with fluorine 18-fluorodeoxyglucose positron emission tomography (FDG-PET). Results Early and spectacular response to infliximab was demonstrated by FDG-PET, which evidenced complete response to treatment. Conclusion This case supports use of FDG-PET to evaluate the extent of active disease in refractory sarcoidosis and above all, FDG-PET could be an imaging method of choice showing response to infliximab in refractory sarcoidosis earlier than other imaging techniques. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect